Modulating the antitumor immunity of MBT-2 murine bladder tumor bearing mice by postoperative administration of interferon-α

Anticancer Research

Volumn 18, Issue 5 A, 1998, Pages 3355-3361

  Tzai, Tzong Shin ^a   Shiau, Ai Li ^a   Wu, Chao Liang ^a   Chow, Nan Haw ^a   Tsai, Yuh Shyan ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Bladder tumor; Cytokine; Immunotherapy; Interferon

Indexed keywords

ALPHA2B INTERFERON; CD11B ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HERMES ANTIGEN; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER TUMOR; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LYMPHOKINE ACTIVATED KILLER CELL; MEMORY CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; TUMOR MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; FEMALE; IMMUNOTHERAPY; INTERFERON ALFA-2B; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; MICE; MICE, INBRED C3H; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0031761902     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Fideler IJ, Balch CM. The biology of cancer metastasis and implications for therapy. Curr Prog Surg 24: 137-209,1987.
2. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E: Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172: 1217-1224,1990.
3. Banneriji R, Arroyo CD, Cordon-Cardo C, Gilboa E: The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol 152: 2324-2232, 1994.
4. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E: Regression of bladder tumors in mice treated with Interleukin 2 gene-modified tumor cells. J Exp Med 177: 1127-1134,1993.
5. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543,1993.
6. Tzai TS, Shiau AL, Lin CS, Wu CL, Lin JSN: Modulation of the immunostimulating effect of autologous tumor vaccine by anti-TGF-ß antibody and interferon-α on murine MBT-2 bladder cancer. Anticancer Res 17: 1073-1078, 1997.
7. Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, Restifo NP, Topalian SL, Simonis TB, Rosenberg SA, Marincola FM: Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 55: 3149-3157, 1995.
8. Tzai TS, Lin SN: Interferon-α can alter the lytic susceptibility of murine bladder transitional cell carcinoma (MBT-2) by their original poor specific cytotoxic tumor infiltrating lymphocytes. J Urol 147: 523-527, 1992.
9. Sancho L, Martinez C, Nogales A, de la Hera A: Reconstitution of natural killer cell activity in the newborn by interleukin-2. N Engl J Med 314: 57-58, 1988.
10. Vaquer S, de la Hera A, Jorda J, Martinez AC, Escudero M, Alvarez-mon, M: Diminished natural killer activity in pregnancy; Modulation by interleukin 2 and interferon. Scand J Immunol 26: 691-698, 1987.
11. Carballido J, Molto L, Manzano L, Olivier C, Salmeron O, Alveraez-Mon M: Interferon α2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder. Cancer 72: 1743-1748, 1993.
12. Alvarez-Mon M, Salmeron OJ, Manzano L, Rodriguez-Zapata M, Reyes E, Vaquer LMS, Carballido J: Alpha interferon as an immunomodulator in the treatment of patients with tumors. Med Oncol 12: 15-21, 1995.
13. Lesley J, Hyman R, Kincade PW: CD44 and its interaction with extracellular matrix. Adv Immunol 54: 271-335, 1993.
14. Pales ST, Koopman G, Heider KH, Griffioen A, Adolf GR, Van den Berg F, Ponta H, Herrlich P, Horst E: CD44 splice variants: expression during lymphocyte activation and tumor progression. Behring Institute Mitteilungen 92: 273-277, 1993.
15. Ross GD, Vetvicka V: CR3(CD11b,CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. Clin Exp Immunol 92: 181-184, 1993.